The pursuit of a cure for Alzheimer’s disease is becoming an increasingly competitive and contentious quest with recent years witnessing several important controversies.

In July 2022, Science magazine reported that a key 2006 research paper, published in the prestigious journal Nature, which identified a subtype of brain protein called beta-amyloid as the cause of Alzheimer’s, may have been based on fabricated data.

One year earlier, in June 2021, the US Food and Drug Administration had approved aducanumab, an antibody-targeting beta-amyloid, as a treatment for Alzheimer’s, even though the data supporting its use were incomplete and contradictory.

An ischemic stroke is a type of stroke that occurs when a blood clot in an artery, also known as thrombus, or the progressive narrowing of arteries, blocks the blood and oxygen flowing to the brain. This process can cause both temporary and permanent brain damage, for instance, leading to partial paralysis, cognitive impairments and other debilitating impairments.

Statistics suggest that older age increases the risk of experiencing ischemic strokes. While neuroscience studies have shed light on many of the physiological processes underpinning strokes, the immune responses following these events and promoting recovery remain poorly understood.

Researchers at the Institut Blood and Brain @ Caen-Normandie (BB@C), University of Edinburgh and other institutes in Europe carried out a study exploring how central nervous system (CNS)-associated macrophages (CAMs), immune cells residing at the CNS interfaces, contribute to post-stroke immune responses.

Researchers have developed a new two-photon fluorescence microscope that captures high-speed images of neural activity at cellular resolution. By imaging much faster and with less harm to brain tissue than traditional two-photon microscopy, the new approach could provide a clearer view of how neurons communicate in real time, leading to new insights into brain function and neurological diseases.